Belpointe Asset Management LLC Sage Therapeutics, Inc. Transaction History

Belpointe Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $102,801 - $156,745	-1,760 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$41.13 - $62.45 $72,388 - $109,912	1,760 New	1,760 $108,000
Q1 2020 Jul 20, 2020	SELL	$26.15 - $77.24 $46,860 - $138,414	-1,792 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$60.18 - $154.77 $15,045 - $38,692	-250 Reduced 12.24%	1,792 $129,000
Q1 2019 Jun 11, 2019	BUY	$89.33 - $163.65 $182,411 - $334,173	2,042 New	2,042 $325,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.